Trevi Therapeutics Inc
TRVI7.450USD
+0.120+1.64%
Market hours （ET）Quotes delayed by 15 min
744.20MMarket Cap
LossP/E TTM
More Details of Trevi Therapeutics Inc Company
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
Company Info
Ticker SymbolTRVI
Company nameTrevi Therapeutics Inc
IPO dateMay 07, 2019
CEOMs. Jennifer L. Good
Number of employees26
Security typeOrdinary Share
Fiscal year-endMay 07
Address195 Church St Fl 14
CityNEW HAVEN
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code06510-2009
Phone12033042499
Websitehttps://www.trevitherapeutics.com/
Ticker SymbolTRVI
IPO dateMay 07, 2019
CEOMs. Jennifer L. Good
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
352.49K
--
Dr. Thomas R. Sciascia, M.D.
Dr. Thomas R. Sciascia, M.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
214.43K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
213.31K
--
Dr. Farrell Simon, Pharm.D.
Dr. Farrell Simon, Pharm.D.
Chief Commercial Officer
Chief Commercial Officer
76.90K
+68.46%
Ms. Lisa Delfini, CPA
Ms. Lisa Delfini, CPA
Chief Financial Officer
Chief Financial Officer
64.66K
+20.65%
Ms. Anne M. Vanlent
Ms. Anne M. Vanlent
Independent Director
Independent Director
25.98K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Independent Director
Independent Director
6.35K
--
Dr. James V. (Jim) Cassella, Ph.D.
Dr. James V. (Jim) Cassella, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Dominick C. Colangelo
Mr. Dominick C. Colangelo
Independent Director
Independent Director
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
352.49K
--
Dr. Thomas R. Sciascia, M.D.
Dr. Thomas R. Sciascia, M.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
214.43K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
213.31K
--
Dr. Farrell Simon, Pharm.D.
Dr. Farrell Simon, Pharm.D.
Chief Commercial Officer
Chief Commercial Officer
76.90K
+68.46%
Ms. Lisa Delfini, CPA
Ms. Lisa Delfini, CPA
Chief Financial Officer
Chief Financial Officer
64.66K
+20.65%
Ms. Anne M. Vanlent
Ms. Anne M. Vanlent
Independent Director
Independent Director
25.98K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jun 18
Updated: Wed, Jun 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
New Enterprise Associates (NEA)
9.69%
Frazier Life Sciences Management, L.P.
8.75%
Rubric Capital Management LP
7.27%
BlackRock Institutional Trust Company, N.A.
3.88%
The Vanguard Group, Inc.
3.27%
Other
67.13%
Shareholders
Shareholders
Proportion
New Enterprise Associates (NEA)
9.69%
Frazier Life Sciences Management, L.P.
8.75%
Rubric Capital Management LP
7.27%
BlackRock Institutional Trust Company, N.A.
3.88%
The Vanguard Group, Inc.
3.27%
Other
67.13%
Shareholder Types
Shareholders
Proportion
Hedge Fund
25.08%
Investment Advisor
14.94%
Investment Advisor/Hedge Fund
14.65%
Venture Capital
13.56%
Private Equity
9.70%
Research Firm
0.95%
Individual Investor
0.83%
Pension Fund
0.27%
Bank and Trust
0.14%
Other
19.88%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
229
94.00M
80.14%
+6.07M
2025Q1
226
89.66M
76.74%
+2.50M
2024Q4
177
80.67M
91.74%
+11.34M
2024Q3
156
59.14M
78.18%
-6.31M
2024Q2
148
56.93M
80.80%
-4.85M
2024Q1
147
52.57M
76.38%
-8.69M
2023Q4
131
54.54M
85.48%
-544.63K
2023Q3
124
54.64M
88.55%
-1.52M
2023Q2
115
54.75M
93.54%
+3.66M
2023Q1
80
49.31M
85.27%
-2.88M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
New Enterprise Associates (NEA)
11.37M
9.69%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
10.26M
8.75%
-405.37K
-3.80%
Mar 31, 2025
Rubric Capital Management LP
4.54M
3.87%
+333.41K
+7.93%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.55M
3.88%
+1.06M
+30.17%
Mar 31, 2025
The Vanguard Group, Inc.
3.84M
3.27%
+328.82K
+9.37%
Mar 31, 2025
Vivo Capital, LLC
3.49M
2.97%
--
--
Mar 31, 2025
MPM BioImpact LLC
3.43M
2.92%
+333.47K
+10.77%
Mar 31, 2025
Octagon Capital Advisors LP
3.32M
2.83%
+3.32M
--
Mar 31, 2025
Viking Global Investors LP
3.23M
2.75%
-1.17M
-26.64%
Mar 31, 2025
Armistice Capital LLC
2.99M
2.55%
+2.99M
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco Dorsey Wright Healthcare Momentum ETF
1.6%
SPDR S&P Pharmaceuticals ETF
0.97%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.69%
ALPS Medical Breakthroughs ETF
0.44%
iShares Micro-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Growth ETF
0.03%
ProShares Hedge Replication ETF
0.02%
View more
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.6%
SPDR S&P Pharmaceuticals ETF
Proportion0.97%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion0.69%
ALPS Medical Breakthroughs ETF
Proportion0.44%
iShares Micro-Cap ETF
Proportion0.09%
Invesco Nasdaq Biotechnology ETF
Proportion0.06%
ProShares Ultra Nasdaq Biotechnology
Proportion0.06%
iShares Biotechnology ETF
Proportion0.03%
iShares Russell 2000 Growth ETF
Proportion0.03%
ProShares Hedge Replication ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
